Clinical trial
Azacitidine and Erythropoietin Versus Azacitidine Alone for Patients With…
NCT00379912 · Larry Cripe, MD, Other · Terminated
Key facts
| NCT number | NCT00379912 |
|---|---|
| Title | Azacitidine and Erythropoietin Versus Azacitidine Alone for Patients With Low-Risk Myelodysplastic Syndromes |
| Official title | Phase II Randomized Trial With A Modified Dose & Schedule of Subcutaneously Administered Azacitidine & Erythropoietin v Azacitidine Alone in Patients With Low-Risk Myelodysplastic Syndromes (Less Than 11% Marrow & Peripheral Blood Blasts) |
| Lead sponsor | Larry Cripe, MD, Other |
| Collaborators | Celgene Corporation Industry Ortho Biotech Clinical Affairs, L.L.C. Walther Cancer Institute |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Myelodysplastic Syndromes |
| Intervention type | Drug |
| Interventions | Azacitidine, Erythropoietin, Azacitidine (Monotherapy) |
| Enrollment | 15 |
| Start date | Sep 1, 2006 |
| Primary completion | Dec 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Sep 25, 2006 |
| Last update posted | Feb 14, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: